# Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial

*PRI Rank #10 · Topics and Trends in Most Cited Cancer-related Molecular Pathways Papers, Class of 2026*

*Canonical URL: https://pri.pepkio.com/top-papers/cancer-related-molecular-pathways/2026/rank-10*

| Field | Value |
| --- | --- |
| Rank | #10 |
| 18m citations | 63 |
| Journal | Journal of Clinical Oncology |
| Year | 2024 |
| DOI | 10.1200/jco-24-02086 |
| Corresponding authors | Kevin Kalinsky |
| Institution | Winship Cancer Institute, United States |

**Ranking page:** [Topics and Trends in Most Cited Cancer-related Molecular Pathways Papers, Class of 2026](https://pri.pepkio.com/top-papers/cancer-related-molecular-pathways/2026)

**Paper link:** [10.1200/jco-24-02086](https://doi.org/10.1200/jco-24-02086)

## Topics

abemaciclib · fulvestrant · CDK4/6 inhibitor · endocrine therapy · hormone receptor-positive breast cancer · HER2-negative breast cancer · advanced breast cancer · progression-free survival · aromatase inhibitor · ESR1 mutations · PIK3CA mutation · Overall response rate · blinded independent central review · postMONARCH trial · treatment rechallenge · acquired resistance

## Cite this ranking

```
Pepkio Research Index (PRI). Topics and Trends in Most Cited Cancer-related Molecular Pathways Papers, Class of 2026. https://pri.pepkio.com/top-papers/cancer-related-molecular-pathways/2026. Accessed 2026-10-28.

Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459
```